Table 1 Study population demographic data and characteristics
From: Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
N | % | |
|---|---|---|
Patient population | 45,360 | 100 |
Gender | ||
Female | 21,826 | 48.12 |
Male | 23,534 | 51.88 |
Race/ethnicity | ||
Black | 9988 | 22.02 |
Hispanic | 15,968 | 35.2 |
White | 16,860 | 37.17 |
Other | 2544 | 5.61 |
Hepatic injury | 28,310 | 62.41 |
Pancreatic injury | 825 | 1.82 |
Hepatic and/or pancreatic injury | 28,495 | 62.82 |
Chronic liver disease (liver cirrhosis) | 2171 | 4.79 |
Alcohol use | 1386 | 3.06 |
Pancreatitis | 366 | 0.81 |
Cholelithiasis/cholecystitis | 943 | 2.08 |
Nausea and vomiting | 756 | 1.67 |
Diarrhea | 1355 | 2.99 |
Antiviral use | 2800 | 6.17 |
Antibiotic use | 19,109 | 42.13 |
Corticosteroids use | 5078 | 11.19 |
Mortality | 6604 | 14.56 |
Disease severity | ||
Mild/moderate | 6484 | 14.29 |
Severe | 25,849 | 56.99 |
Critical | 13,027 | 28.72 |